MedTrace Logo

QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study

NCT05733559 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 565

Last updated 2023-12-05

No results posted yet for this study

Summary

This study will evaluate the clinical performance of the QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target with a validated comparator method

Conditions

  • Respiratory Disease

Interventions

DEVICE

QIAstat-Dx® Respiratory Panel Plus (RPP)

An observational prospective performance evaluation study of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target against a marketed comparator, using NPS collected per the manufacturer's instructions and eluted in Universal Transport Media (UTM) from subjects with signs and symptoms of respiratory infection

Sponsors & Collaborators

  • QIAGEN Gaithersburg, Inc

    lead INDUSTRY

Principal Investigators

  • Sarah Johnson · QIAGEN Gaithersburg, Inc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-23
Primary Completion
2023-05-03
Completion
2023-10-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733559 on ClinicalTrials.gov